美罗华联合CHOP方案治疗B细胞性非霍奇金淋巴瘤效果观察

［摘要］　目的　探讨美罗华联合CHOP方案治疗B细胞性非霍奇金淋巴瘤的临床效果及不良反应。方法　选择B细胞性非霍奇金淋巴瘤60例随机分成观察组和对照组各30例。观察组采用美罗华联合CHOP方案治疗,对照组仅采用CHOP方案治疗,比较两组临床疗效及不良反应情况。结果　观察组患者临床疗效明显优于对照组(P<0.05);不良反应除发热例数多于对照组外（P<0.05）,其余两组比较差异无统计学意义（P>0.05）。结论　对B细胞性非霍奇金淋巴瘤患者采用美罗华联合CHOP方案治疗,能够有效提高患者的临床疗效,值得临床推广。     

异丙嗪联合丹参川芎嗪治疗眩晕症的临床观察

［摘要］　目的　观察异丙嗪联合丹参川芎嗪治疗眩晕症的临床疗效。方法　选择2011-02～2013-04该院收治的114例眩晕症患者随机分为治疗组和对照组各57例。治疗组给予盐酸异丙嗪,联合丹参川芎嗪治疗;对照组单用盐酸异丙嗪治疗。比较两组的临床疗效、症状消失时间、得分情况以及不良反应。结果　治疗3 d后,治疗组临床疗效高于对照组(P<0.05)。治疗组的眩晕、植物神经症状、耳蜗综合征、前庭功能受损等症状消失时间均明显快于对照组（P<0.01）,症状得分明显低于对照组（P<0.01）。两组不良反应均较轻微,采取相应措施后均消失。结论　异丙嗪联合丹参川芎嗪治疗眩晕症的临床疗效显著,具有推广价值。     

头孢哌酮钠舒巴坦钠联合左氧氟沙星治疗医院获得性肺炎的临床疗效观察

［摘要］　目的　探讨头孢哌酮钠舒巴坦钠联合左氧氟沙星治疗医院获得性肺炎（hospital acquired pneumonia,HAP）的临床疗效和不良反应。方法　将42例HAP确诊病例随机分为治疗组和对照组,每组21例。治疗组用头孢哌酮钠舒巴坦钠联合左氧氟沙星治疗,对照组用头孢哌酮钠舒巴坦钠治疗,疗程均为7～8 d。 结果　治疗组症状、体征恢复正常的时间为（48.24±7.54）h,对照组为（72.36±10.24）h,两组比较差异有统计学意义（P<0.01）;治疗组的临床疗效优于对照组（P<0.05);两组不良反应发生率比较差异无统计学意义（P>0.05)。结论　头孢哌酮钠舒巴坦钠联合左氧氟沙星治疗HAP的疗效明显优于单用头孢哌酮钠舒巴坦钠,值得临床推广应用。     

前后入路联合内固定治疗颈椎病的手术配合体会

［摘要］　目的　观察应用无缝隙配合模式对颈椎病患者在接受前后入路联合内固定手术治疗的过程中实施手术配合的临床效果。方法　将88例接受前后入路联合内固定手术治疗的颈椎病患者随机分为对照组和观察组,每组44例。对照组采用常规配合模式实施手术配合;观察组采用无缝隙配合模式实施手术配合。结果　 两组治疗效果差异无统计学意义（P>0.05）;观察组内固定手术操作时间、术后颈椎功能恢复正常时间、术后接受恢复治疗时间明显短于对照组（P<0.05）;围手术期出现不良反应的例数明显少于对照组（P<0.05）;手术护理模式患者满意度明显高于对照组（P<0.05）;治疗后颈椎病再次复发率明显低于对照组（P<0.05）。结论　应用无缝隙配合模式对颈椎病患者在接受前后入路联合内固定手术治疗的过程中实施手术配合有较好的治疗效果。     

康艾注射液联合化疗对肺鳞癌患者临床疗效和免疫功能及生活质量的影响

［摘要］　目的　探讨康艾注射液联合化疗对晚期肺鳞癌患者临床疗效和免疫功能及生活质量的影响。方法　收集2017年7月至2020年10月广东医科大学附属医院94例肺鳞癌初治患者,按照随机数字表法分为对照组（45例）和观察组（49例）。对照组接受顺铂+吉西他滨化疗,观察组在对照组的基础上联合康艾注射液辅助治疗,两组均治疗4个疗程。比较两组治疗前后T细胞计数、治疗后的临床疗效、生活质量评分及化疗不良反应情况。结果　治疗后,观察组的客观缓解率高于对照组,差异有统计学意义（P<0.05）,但两组的疾病控制率差异无统计学意义（P>0.05）;观察组KPS评分高于对照组,差异有统计学意义（P<0.05）;观察组T淋巴细胞总数、T辅助细胞绝对值、T抑制细胞绝对值高于对照组,差异有统计学意义（P<0.05）;观察组恶心呕吐、血小板减少、白细胞减少不良反应发生率低于对照组,差异有统计学意义（P<0.05）。结论　康艾注射液联合化疗可提高晚期肺鳞癌患者免疫功能和生活质量,降低不良反应,从而提高临床疗效,值得临床推广。     

强化髋关节周围肌肉力量训练对髌股关节疼痛综合征的疗效观察

［摘要］　目的　观察强化髋关节周围肌肉力量训练对髌股关节疼痛综合征（PFPS）的疗效。方法　选择2018年6月至2019年6月该院收治的PFPS患者60例,采用抽签法将其分为观察组和对照组,每组30例。对照组予常规物理治疗,观察组在对照组治疗方案的基础上增加髋关节周围肌肉力量训练。比较两组治疗前后的膝前痛量表（AKPS）评分、视觉模拟量表（VAS）评分以及屈膝、伸膝的最大峰力矩（PT）。结果　治疗后,两组AKPS评分均提高,VAS评分均降低,与治疗前比较差异均有统计学意义（P<0.05）。与对照组比较,观察组治疗后AKPS评分更高、VAS评分更低,差异有统计学意义（P<0.05）。治疗后,两组伸膝、屈膝PT值均提高,与治疗前比较差异均有统计学意义（P<0.05）。与对照组比较,观察组治疗后的伸膝、屈膝PT值更高,差异有统计学意义（P<0.05）。结论　强化髋关节周围肌肉力量训练有利于改善PFPS患者的膝关节活动功能,减轻膝关节疼痛症状,疗效显著。     

外剥内扎术联合美辛唑酮栓治疗混合痔Ⅲ期的临床研究

［摘要］　目的　观察应用外剥内扎术联合美辛唑酮栓治疗混合痔Ⅲ期的临床效果。方法　选择该院肛肠外科2012-01～2013-03住院的混合痔Ⅲ期患者60例,将患者随机分为治疗组和对照组,对照组30例采用常规手术治疗。治疗组30例,在常规治疗的基础上直肠腔置美辛唑酮栓1枚,术后第1天开始换药时将美辛唑酮栓塞入肛内。观察两组患者术后治疗效果。结果　治疗组疗效优于对照组（P<0.05）,治疗组住院天数短于对照组（P<0.01）,治疗组的疼痛、水肿、坠胀、出血程度均低于对照组（P<0.05或P<0.01）。结论　混合痔Ⅲ期应用外剥内扎术联合美辛唑酮栓治疗,解决了术后镇痛、恢复时间长、并发症多等问题,值得临床推广使用。     

电刺激联合生物反馈治疗中老年女性压力性尿失禁57例临床观察

［摘要］　目的　探讨电刺激联合生物反馈治疗中老年女性压力性尿失禁的效果。方法　采用法国PHENIX神经肌肉刺激治疗仪对57例中老年妇女压力性尿失禁患者治疗1～2个疗程，治疗3个月后进行随访、复诊，评价疗效。结果　57例患者治愈21例（36.8%），有效24例（42.1%），无效12例（21.1%），总有效率为78.9%。子宫脱垂和阴道膨出的患者均感到脱出物有不同程度的回缩。34例性生活不满意患者均有不同程度改善。盆底肌Ⅰ类肌纤维疲劳度改善不明显（P>0.05），Ⅱ类肌纤维疲劳度、Ⅰ类及Ⅱ类肌肌力、每周平均漏尿次数、A3反射异常、综合肌电位值均明显改善（P<0.05）。结论　电刺激联合生物反馈是治疗中老年女性压力性尿失禁的一种有效、简便、无创伤的方法，值得推广。     

体外膈肌起搏器联合吞咽功能训练对脑卒中后吞咽障碍改善的作用观察

［摘要］　目的　观察体外膈肌起搏器（EDP）联合吞咽功能训练对脑卒中后吞咽障碍改善的作用。方法　将2017-04～2020-05该院80例脑卒中后吞咽障碍患者按随机数字表法分为观察组和对照组,每组40例,中途退出4例,最终纳入统计为76例,对照组39例,观察组37例。对照组给予吞咽功能基础训练,观察组在吞咽功能基础训练的基础上联合应用EDP进行治疗。治疗前与治疗4周后,使用标准吞咽功能评定量表(SSA)和中文版吞咽生存质量量表（SWAL-QOL）评估两组患者吞咽功能和生存质量,比较两组观察期肺炎的发生率。结果　治疗4周后,两组患者的SSA评分较治疗前降低（P<0.01）,SWAL-QOL评分较治疗前提高（P<0.01）,且观察组优于对照组（P<0.05）;观察组肺炎发生率为8.1%,低于对照组的33.3%（P<0.05）。结论　EDP联合吞咽功能基础训练可明显改善脑卒中后患者吞咽功能,降低肺炎发生率,改善生存质量,且效果优于单纯进行吞咽功能基础训练,值得推广。     

血塞通低分子右旋糖酐联合神经节苷脂治疗急性脑梗死疗效观察

［摘要］　目的　观察血塞通低分子右旋糖酐联合神经节苷脂治疗急性脑梗死的疗效。方法　选择急性脑梗死患者98例,半随机分为两组。治疗组57例用血塞通粉针加入低分子右旋糖酐联合神经节苷脂治疗;对照组41例用丹参川芎嗪、胞二磷胆碱和维脑路通注射液治疗,疗程14 d。结果　治疗组临床疗效优于对照组(P<0.05),治疗组的神经功能缺损评分减少程度明显大于对照组（P<0.01）,未发现明显副作用。结论　血塞通低分子右旋糖酐联合神经节苷脂治疗急性脑梗死是一种安全有效的治疗方案,值得临床推广。     

Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo

Pyronaridine is a Mannich base anti-malarial with demonstrated efficacy against drug resistant Plasmodium falciparum, P. vivax, P. ovale and P. malariae. However, resistance to pyronaridine can develop quickly when it is used alone but can be considerably delayed when it is administered with artesunate in rodent malaria models. The aim of this study was to evaluate the efficacy of pyronaridine in combination with artesunate against P. falciparum in vitro and in rodent malaria models in vivo to support its clinical application. Pyronaridine showed consistently high levels of in vitro activity against a panel of six P. falciparum drug-sensitive and resistant strains (Geometric Mean IC50=2.24 nM, 95% CI=1.20-3.27). In vitro interactions between pyronaridine and artesunate showed a slight antagonistic trend, but in vivo compared to pyronaridine and artesunate administered alone, the 3:1 ratio of the combination, reduced the ED90 of artesunate by approximately 15.6-fold in a pyronaridine-resistant P. berghei line and by approximately 200-fold in an artesunate-resistant line of P. berghei. Complete cure rates were achieved with doses of the combination above or equal to 8 mg/kg per day against P. chabaudi AS. These results indicate that the combination had an enhanced effect over monotherapy and lower daily doses of artesunate could be used to obtain a curative effect. The data suggest that the combination of pyronaridine and artesunate should have potential in areas of multi-drug resistant malaria.     

Modulation of enterotoxin binding and function in vitro and in vivo

The use of the nontoxic B subunits of cholera and Escherichia coli enterotoxins in vitro and in vivo led to a decrease in toxin binding to target cells and a decrease in toxin-induced effects (i.e., morphological effects, adenylate cyclase activation, and fluid secretion). The reduction in toxin binding involves a process of down-regulation of cellular receptors for the toxin and not toxin occupancy of receptors. The extent of inhibition was dependent on the amount of B subunit used and on the duration of time after its use. Thus, in vivo exposure to a single bolus of B subunit was sufficient to block toxin binding and activity for up to 18 h. Because the B subunit binds extensively to the esophagus and the stomach, peroral administration will require a preparation that allows the subunit to reach the small bowel in a protected form. Our data provide a rationale for using B subunit therapy for short-term protection against the effects of enterotoxins, before the development of an immune response.     

我国高血压防治现状和策略

<正>我国现患高血压2亿人,由于人群高血压患病率的不断升高和防控力度不够,我国高血压人群的知晓率、治疗率、控制率仍处于较低水平。对于像高血压这样的群体性慢性病,应当采取全人     

Cooperation of B- and T-lymphocytes of the human in vitro and in vivo

It is reported on the experimental proofs for the existence of a cooperation of different populations of lymphocytes in man. Regulatory lymphocytes play a part in the regulation of the synthesis of immunoglobulins by polyclonally stimulated B-lymphocytes, in the generation of killer-T-cells and in the regulation of the DNA-synthesis by mitogenically stimulated T- and B-cells. Typical helper- and suppressor-effects may be proved. Disturbances of lymphocytic interactions may be a cause for the development of immune deficiency diseases. It is very probable that also in several chronic infections a dysfunction of regulatory T-lymphocytes is present.     

Uptake of labeled alloxan in mouse organs and mitochondria in vivo and in vitro

[14C]2-Alloxan was administered in vivo and in vitro for study of the uptake of alloxan in different organs and their mitochondia of mice. After in vivo administration, radioactivity was demonstrated in all organs investigated, with quantitative differences: endocrine pancreas greater than liver greater than exocrine pancreas and heart. No significant difference was found between the iv and ip routes of injection. An in vivo uptake of alloxan was also found in mitochondria, with significant quantitative differences as to the origin of the organelles: endocrine pancreas greater than liver greater than exocrine pancreas and heart. Pretreatment with D-glucose caused significantly decreased uptake in liver, exocrine pancreas, and heart, but significantly increased uptake in endocrine pancreas, whereas the uptake was significantly decreased in the mitochondria from all of these organs. In vitro uptake was observed in all kinds of mitochondria studied. This uptake was higher than the in vivo uptake in mitochondria from liver, exocrine pancreas, and heart, whereas the uptake in vivo was higher than the in vitro uptake in islet mitochondria. The presence of D-glucose did not affect the in vitro uptake of alloxan in mitochondria. The findings show that in vivo, alloxan passes across plasma membranes and is taken up by mitochondria, and data obtained with mitochondrial subfractions may also indicate a passage across mitochondrial membranes. D-Glucose protection against alloxan diabetogenicity may be associated with prevention of mitochondrial uptake of alloxan. This prevention seems to be dependent on the metabolism of glucose.